Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Switch-Maintenance Prophylaxis of GVHD in Allo-HCT
NCT07359859Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07359859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359859.